How to Help Your Patients Find Incruse Ellipta in Stock: A Provider's Guide

COPD is a chronic, progressive disease that requires consistent daily medication. When a patient calls your office saying they can't fill their Incruse Ellipta prescription, the response matters — both for their clinical outcomes and their confidence in their care team. This guide gives you a practical framework for helping COPD patients access Incruse Ellipta (umeclidinium) when pharmacy availability becomes a barrier.

Understanding Why Patients Can't Find Incruse Ellipta

Before sending a patient on a pharmacy search, it helps to diagnose why they can't get their medication. The issue typically falls into one of three categories:

• Physical availability: The pharmacy does not have Incruse Ellipta in stock. This is a stocking or distribution issue.
• Coverage or authorization: The pharmacy has it but the prescription is being blocked by an insurance issue — expired prior auth, step therapy requirements, or quantity limits.
• Cost: The patient has coverage or is uninsured, but the out-of-pocket cost ($350–$415 without assistance) is prohibitive.

Ask your staff to triage the call by determining which barrier applies before taking action. A patient blocked by a prior auth needs a different intervention than one who simply went to the wrong pharmacy.

Step 1: Direct Patients to medfinder to Find Available Pharmacies

For pharmacy availability issues, the most efficient first step is to direct patients to medfinder. medfinder is a service that calls pharmacies near the patient's location to check which ones can fill their specific prescription, then texts the patient the results. This replaces the frustrating process of patients calling multiple pharmacies themselves and getting put on hold or receiving inconsistent information.

A simple script your staff can use:

"Mr./Ms. [Patient name], I'd recommend visiting medfinder.com — it's a service that calls pharmacies near you to check which ones have your Incruse Ellipta in stock. You enter your zip code and medication, and they text you the results. That way you don't have to call around yourself."

Step 2: Offer Samples to Bridge Gaps

GSK provides Incruse Ellipta samples to prescribing practices. If your office maintains a sample inventory, check for Incruse Ellipta — a 7- or 30-day sample can bridge a patient through a temporary stockout while they locate a pharmacy or wait for a reorder. If you don't have samples on hand, contact your GSK territory representative to request them. Having Incruse Ellipta samples in stock is particularly valuable for newly diagnosed COPD patients who need to start therapy immediately while insurance coverage is being established.

Step 3: Verify and Renew Prior Authorization Proactively

Review your COPD patient panel to identify patients on Incruse Ellipta whose prior authorizations are expiring in the next 60–90 days. Proactively renewing PA before it expires prevents patients from experiencing a gap in coverage that looks like a medication availability problem. Common PA documentation requirements include:

• Current COPD diagnosis with spirometry (FEV1/FVC < 0.70 post-bronchodilator)
• Documentation of GOLD stage and symptom burden (CAT score or mMRC dyspnea scale)
• Step therapy compliance (prior trial of short-acting bronchodilators or tiotropium, if required)
• Letter of medical necessity for plans with more restrictive criteria

Step 4: Connect Patients With GSK Savings Programs

If cost is a barrier, two programs can significantly reduce out-of-pocket expenses:

• GSK "Pay No More Than $35" coupon: For commercially insured patients. Caps copay at $35/month for up to 12 fills. Direct patients to gsksavings.com or the pharmacy counter. Available starting January 1, 2025.
• GSK For You Patient Assistance Program: Income-based assistance for uninsured or underinsured patients. Eligibility varies. Call 866-728-4368 or visit gskforyou.com.

Step 5: When to Consider Switching to an Alternative

If the access issue is persistent — rather than a one-time stockout — it may be appropriate to consider a therapeutic switch. Before switching, assess:

• Is the patient well-controlled on Incruse Ellipta? (FEV1 improvement, symptom reduction)
• Is the access issue due to formulary restrictions that would also block alternatives?
• Is the patient comfortable learning a new inhaler device?

For patients who need a LAMA-only option and can't access Incruse Ellipta, tiotropium (Spiriva HandiHaler or Respimat) is the most readily stocked alternative with comparable clinical efficacy. If stepping up is warranted, Anoro Ellipta (umeclidinium + vilanterol) may be appropriate and is typically more widely stocked.

Counseling Patients to Be Proactive

Encourage patients to refill their Incruse Ellipta prescriptions at least one week before the inhaler expires (note: each Ellipta inhaler expires 6 weeks after the foil tray is opened and contains 30 doses). Proactive refilling eliminates the urgency that leads to stressful availability searches. For additional patient-facing resources, direct them to our Incruse Ellipta availability guide at medfinder.com.